The role of oxidative stress in Parkinson's disease.

Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. Oxid Med Cell Longev (2015) 1.13

MicroRNA-7 protects against 1-methyl-4-phenylpyridinium-induced cell death by targeting RelA. J Neurosci (2014) 0.89

Alpha-Synuclein Oligomers Interact with Metal Ions to Induce Oxidative Stress and Neuronal Death in Parkinson's Disease. Antioxid Redox Signal (2016) 0.89

Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease. EMBO Mol Med (2015) 0.88

Lithium protects against paraquat neurotoxicity by NRF2 activation and miR-34a inhibition in SH-SY5Y cells. Front Cell Neurosci (2015) 0.87

Mitochondrial Dysfunction and α-Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First? Parkinsons Dis (2015) 0.86

Accelerating neuronal aging in in vitro model brain disorders: a focus on reactive oxygen species. Front Aging Neurosci (2014) 0.86

Mitochondria: A Therapeutic Target for Parkinson's Disease? Int J Mol Sci (2015) 0.85

LC/MS analysis of cardiolipins in substantia nigra and plasma of rotenone-treated rats: Implication for mitochondrial dysfunction in Parkinson's disease. Free Radic Res (2015) 0.82

Transducing oxidative stress to death signals in neurons. J Cell Biol (2015) 0.82

Brain mitochondria from DJ-1 knockout mice show increased respiration-dependent hydrogen peroxide consumption. Redox Biol (2014) 0.81

Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases. J Parkinsons Dis (2015) 0.81

Mitochondrial dysfunction and cell death in neurodegenerative diseases through nitroxidative stress. Brain Res (2016) 0.81

Mitochondrial dysfunction in cardiac aging. Biochim Biophys Acta (2015) 0.80

Poststroke Induction of α-Synuclein Mediates Ischemic Brain Damage. J Neurosci (2016) 0.80

Oxidized DJ-1 as a possible biomarker of Parkinson's disease. J Clin Biochem Nutr (2014) 0.80

Mitochondria-Targeted Protective Compounds in Parkinson's and Alzheimer's Diseases. Oxid Med Cell Longev (2015) 0.80

H2O2-Induced Oxidative Stress Affects SO4= Transport in Human Erythrocytes. PLoS One (2016) 0.79

MicroRNA-7 Promotes Glycolysis to Protect against 1-Methyl-4-phenylpyridinium-induced Cell Death. J Biol Chem (2015) 0.79

Nutritional status, oxidative stress and dementia: the role of selenium in Alzheimer's disease. Front Aging Neurosci (2014) 0.79

Associations between B Vitamins and Parkinson's Disease. Nutrients (2015) 0.79

Oxidative and nitrosative stress in serum of patients with Parkinson's disease. Neurol Sci (2016) 0.79

Isothiocyanates Are Promising Compounds against Oxidative Stress, Neuroinflammation and Cell Death that May Benefit Neurodegeneration in Parkinson's Disease. Int J Mol Sci (2016) 0.79

Evaluation of the Inhibitory Effects of Bavachinin and Bavachin on Human Monoamine Oxidases A and B. Evid Based Complement Alternat Med (2015) 0.78

Neuroprotective effects of Liriope platyphylla extract against hydrogen peroxide-induced cytotoxicity in human neuroblastoma SH-SY5Y cells. BMC Complement Altern Med (2015) 0.78

MicroRNA-7 Regulates the Function of Mitochondrial Permeability Transition Pore by Targeting VDAC1 Expression. J Biol Chem (2016) 0.77

Reactive Oxygen Species: Physiological and Physiopathological Effects on Synaptic Plasticity. J Exp Neurosci (2016) 0.77

The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A Mini Review. Oxid Med Cell Longev (2016) 0.77

Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease. Biomolecules (2015) 0.77

Necrostatin-1 protection of dopaminergic neurons. Neural Regen Res (2015) 0.77

Mitophagy in TGEV infection counteracts oxidative stress and apoptosis. Oncotarget (2016) 0.77

Immunomodulators as Therapeutic Agents in Mitigating the Progression of Parkinson's Disease. Brain Sci (2016) 0.77

SO4(=) uptake and catalase role in preconditioning after H2O2-induced oxidative stress in human erythrocytes. Pflugers Arch (2016) 0.76

Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. Chem Rev (2017) 0.76

Oxidative stress in neurodegenerative disease: causation or association? Oncotarget (2017) 0.76

Depressive symptoms are associated with oxidative stress in middle-aged women: a cross-sectional study. Biopsychosoc Med (2016) 0.76

Absence of glia maturation factor protects dopaminergic neurons and improves motor behavior in mouse model of parkinsonism. Neurochem Res (2015) 0.76

Antioxidants inhibit neuronal toxicity in Parkinson's disease-linked LRRK2. Ann Clin Transl Neurol (2016) 0.76

Selective damage to dopaminergic transporters following exposure to the brominated flame retardant, HBCDD. Neurotoxicol Teratol (2015) 0.76

The Metabolic Fate of ortho-Quinones Derived from Catecholamine Metabolites. Int J Mol Sci (2016) 0.76

Hsp31, a member of the DJ-1 superfamily, is a multitasking stress responder with chaperone activity. Prion (2016) 0.76

C-Terminal Tyrosine Residue Modifications Modulate the Protective Phosphorylation of Serine 129 of α-Synuclein in a Yeast Model of Parkinson's Disease. PLoS Genet (2016) 0.76

Study of Exosomes Shed New Light on Physiology of Amyloidogenesis. Cell Mol Neurobiol (2016) 0.76

Immortalized Parkinson's disease lymphocytes have enhanced mitochondrial respiratory activity. Dis Model Mech (2016) 0.76

Emerging roles of extracellular vesicles in neurodegenerative disorders: focus on HIV-associated neurological complications. Cell Death Dis (2016) 0.76

Genetic Profile, Environmental Exposure, and Their Interaction in Parkinson's Disease. Parkinsons Dis (2016) 0.76

Effects of Oxidative Stress and Testosterone on Pro-Inflammatory Signaling in a Female Rat Dopaminergic Neuronal Cell Line. Endocrinology (2016) 0.76

Mechanisms of Parkinson's disease-related proteins in mediating secondary brain damage after cerebral ischemia. J Cereb Blood Flow Metab (2017) 0.76

Discovery of 3-Arylcoumarin-tetracyclic Tacrine Hybrids as Multifunctional Agents against Parkinson's Disease. ACS Med Chem Lett (2014) 0.75

N-Acetylcysteine in Combination with IGF-1 Enhances Neuroprotection against Proteasome Dysfunction-Induced Neurotoxicity in SH-SY5Y Cells. Parkinsons Dis (2016) 0.75

Translational and post-translational regulation of mouse cation transport regulator homolog 1. Sci Rep (2016) 0.75

Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid. Neurotherapeutics (2016) 0.75

Identification of Multiple QTLs Linked to Neuropathology in the Engrailed-1 Heterozygous Mouse Model of Parkinson's Disease. Sci Rep (2016) 0.75

Apoptosis signal-regulating kinase 1 modulates the phenotype of α-synuclein transgenic mice. Neurobiol Aging (2014) 0.75

Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson's disease by suppressing glycogen synthase kinase-3 beta activity. Acta Pharmacol Sin (2016) 0.75

Glutathione as a Biomarker in Parkinson's Disease: Associations with Aging and Disease Severity. Oxid Med Cell Longev (2016) 0.75

Potential Role of Caffeine in the Treatment of Parkinson's Disease. Open Neurol J (2016) 0.75

Peganum Harmala L. Extract Reduces Oxidative Stress and Improves Symptoms in 6-Hydroxydopamine-Induced Parkinson's Disease in Rats. Iran J Pharm Res (2016) 0.75

Alpha-synuclein prevents the formation of spherical mitochondria and apoptosis under oxidative stress. Sci Rep (2017) 0.75

Serum uric acid levels in patients with Parkinson's disease: A meta-analysis. PLoS One (2017) 0.75

S-nitrosylation of UCHL1 induces its structural instability and promotes α-synuclein aggregation. Sci Rep (2017) 0.75

The Effects of Crocin on 6-OHDA-Induced Oxidative/Nitrosative Damage and Motor Behaviour in Hemiparkinsonian Rats. Malays J Med Sci (2016) 0.75

Andrographolide induces Nrf2 and heme oxygenase 1 in astrocytes by activating p38 MAPK and ERK. J Neuroinflammation (2016) 0.75

Association of NQO1 and TNF polymorphisms with Parkinson's disease: A meta-analysis of 15 genetic association studies. Biomed Rep (2014) 0.75

Chaperone-Mediated Autophagy and Mitochondrial Homeostasis in Parkinson's Disease. Parkinsons Dis (2016) 0.75

Iron Deposition Leads to Neuronal α-Synuclein Pathology by Inducing Autophagy Dysfunction. Front Neurol (2017) 0.75

Upregulation of 3-MST Relates to Neuronal Autophagy After Traumatic Brain Injury in Mice. Cell Mol Neurobiol (2016) 0.75

Increased Oxidative Stress Markers in Cerebrospinal Fluid from Healthy Subjects with Parkinson's Disease-Associated LRRK2 Gene Mutations. Front Aging Neurosci (2017) 0.75

Immunomodulatory Effects Mediated by Dopamine. J Immunol Res (2016) 0.75

Dopaminergic Neurons Respond to Iron-Induced Oxidative Stress by Modulating Lipid Acylation and Deacylation Cycles. PLoS One (2015) 0.75

Copy number variability in Parkinson's disease: assembling the puzzle through a systems biology approach. Hum Genet (2016) 0.75

Formation of covalent di-tyrosine dimers in recombinant α-synuclein. Intrinsically Disord Proteins (2015) 0.75

Morroniside protects SK-N-SH human neuroblastoma cells against H2O2-induced damage. Int J Mol Med (2017) 0.75

Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms. Oxid Med Cell Longev (2016) 0.75

Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease. Sci Rep (2015) 0.75

Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer's disease. PLoS Genet (2017) 0.75

Oxidation and interaction of DJ-1 with 20S proteasome in the erythrocytes of early stage Parkinson's disease patients. Sci Rep (2016) 0.75

Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies. Ann Clin Transl Neurol (2016) 0.75

Re-Cloning the N27 Dopamine Cell Line to Improve a Cell Culture Model of Parkinson's Disease. PLoS One (2016) 0.75

Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications. Oxid Med Cell Longev (2017) 0.75

The efficacy and safety of coenzyme Q10 in Parkinson's disease: a meta-analysis of randomized controlled trials. Neurol Sci (2016) 0.75

Neuroprotection through flavonoid: Enhancement of the glyoxalase pathway. Redox Biol (2017) 0.75

The Treadmill Exercise Protects against Dopaminergic Neuron Loss and Brain Oxidative Stress in Parkinsonian Rats. Oxid Med Cell Longev (2017) 0.75

The Chemical Molecule B355252 is Neuroprotective in an In Vitro Model of Parkinson's Disease. Cell Mol Neurobiol (2015) 0.75

Epigallocatechin Gallate Has a Neurorescue Effect in a Mouse Model of Parkinson Disease. J Nutr (2017) 0.75

Redox regulation of proteasome function. Redox Biol (2017) 0.75

Sorbus alnifolia protects dopaminergic neurodegeneration in Caenorhabditis elegans. Pharm Biol (2017) 0.75

Targeting urate to reduce oxidative stress in Parkinson disease. Exp Neurol (2017) 0.75

Post 6-OHDA lesion exposure to stress affects neurotrophic factor expression and aggravates motor impairment. Metab Brain Dis (2017) 0.75

Behavioral Phenotyping and Pathological Indicators of Parkinson's Disease in C. elegans Models. Front Genet (2017) 0.75

Metabolic Investigations of the Molecular Mechanisms Associated with Parkinson's Disease. Metabolites (2017) 0.75

Are Astrocytes the Predominant Cell Type for Activation of Nrf2 in Aging and Neurodegeneration? Antioxidants (Basel) (2017) 0.75

Thyroid hormone protects hepatocytes from HBx-induced carcinogenesis by enhancing mitochondrial turnover. Oncogene (2017) 0.75

Paraquat-Induced Movement Disorder in Relation to Oxidative Stress-Mediated Neurodegeneration in the Brain of Drosophila melanogaster. Neurochem Res (2017) 0.75

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30

Oxidants, oxidative stress and the biology of ageing. Nature (2000) 23.21

Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol (2006) 21.58

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature (1998) 21.49

Alpha-synuclein in Lewy bodies. Nature (1997) 20.83

alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20

Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol (2008) 17.81

Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science (2004) 15.91

Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature (2006) 15.69

Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35

Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 13.99

How mitochondria produce reactive oxygen species. Biochem J (2009) 13.03

Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature (2006) 11.91

PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol (2010) 11.85

Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature (2006) 11.81

Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci (2007) 11.24

Mitochondrial formation of reactive oxygen species. J Physiol (2003) 10.73

Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science (2002) 9.90

The free radical theory of aging matures. Physiol Rev (1998) 9.83

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science (1983) 9.41

alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A (1998) 8.41

Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet (2000) 7.83

Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet (2004) 7.69

Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci U S A (2003) 7.57

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A (2005) 6.98

Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron (2000) 6.92

Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci U S A (1994) 6.84

Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (2012) 6.66

High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet (2006) 6.52

Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin. J Cell Biol (2010) 5.94

Oxidative stress in Parkinson's disease. Ann Neurol (2003) 5.93

Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci U S A (2006) 5.78

Mitochondrial complex I deficiency in Parkinson's disease. Lancet (1989) 5.72

Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov (2007) 5.65

Levodopa and the progression of Parkinson's disease. N Engl J Med (2004) 5.44

Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin. Proc Natl Acad Sci U S A (2010) 5.17

Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet (2007) 4.99

Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med (1988) 4.98

S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science (2004) 4.97

Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. J Biol Chem (2009) 4.90

Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med (1999) 4.88

Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem (2004) 4.86

Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci U S A (2000) 4.83

The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A (2004) 4.76

Oxidative stress in neurodegeneration: cause or consequence? Nat Med (2004) 4.72

Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem J (1980) 4.62

Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet (2006) 4.61

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol (2002) 4.60

Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol (2008) 4.58

Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci U S A (2008) 4.50

Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science (2001) 4.48

Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet (2010) 4.47

Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy. Hum Mol Genet (2011) 4.41

Clinicopathological correlates in frontotemporal dementia. Ann Neurol (2004) 4.38

Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc Natl Acad Sci U S A (2005) 4.22

Advances in metal-induced oxidative stress and human disease. Toxicology (2011) 4.04

Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med (2012) 3.98

LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J (2007) 3.89

Energy converting NADH:quinone oxidoreductase (complex I). Annu Rev Biochem (2006) 3.88

Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect (2011) 3.87

DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep (2004) 3.84

Mitochondria take center stage in aging and neurodegeneration. Ann Neurol (2005) 3.83

Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci U S A (2005) 3.83

LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell (2011) 3.78

Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol (2006) 3.72

alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology (2007) 3.62

Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J (2005) 3.60

Complex III releases superoxide to both sides of the inner mitochondrial membrane. J Biol Chem (2004) 3.59

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA (2002) 3.46

Dopamine covalently modifies and functionally inactivates parkin. Nat Med (2005) 3.43

DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci U S A (2006) 3.41

Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. Proc Natl Acad Sci U S A (2005) 3.40

Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A (2002) 3.33

Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest (2008) 3.23

Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci (2006) 3.20

Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem (2001) 3.13

Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature (1988) 3.12

Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron (2009) 3.11

Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol (1989) 3.11

Mitochondrial DNA mutations in disease and aging. Environ Mol Mutagen (2010) 3.10

Autophagy and aging: keeping that old broom working. Trends Genet (2008) 3.09

Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem (2010) 3.02

Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol (2009) 3.02

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology (2006) 3.01

DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum Mol Genet (2010) 3.00

Degradation of oxidized proteins by the 20S proteasome. Biochimie (2001) 2.93

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93

Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci (2002) 2.93

Superoxide dismutases. An adaptation to a paramagnetic gas. J Biol Chem (1989) 2.89

Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A (1996) 2.88

DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci U S A (2007) 2.87

Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol (2003) 2.85

Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci (2006) 2.85

Synthesis of nitric oxide in CNS glial cells. Trends Neurosci (1993) 2.81

RNA binding activity of the recessive parkinsonism protein DJ-1 supports involvement in multiple cellular pathways. Proc Natl Acad Sci U S A (2008) 2.76

Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65

Loss of parkin or PINK1 function increases Drp1-dependent mitochondrial fragmentation. J Biol Chem (2009) 2.64

Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A (2002) 2.64

Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem (2004) 2.62

Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J Clin Invest (2003) 2.60

Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science (2002) 4.72

Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci U S A (2009) 2.61

Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem (2003) 2.42

Interaction between mutant ataxin-1 and PQBP-1 affects transcription and cell death. Neuron (2002) 1.95

Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proc Natl Acad Sci U S A (2005) 1.91

Mitochondrial localization of DJ-1 leads to enhanced neuroprotection. J Neurosci Res (2009) 1.68

Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A (2003) 1.40

MicroRNAs in neurodegenerative diseases and their therapeutic potential. Pharmacol Ther (2011) 1.37

Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J Immunol (2010) 1.34

Parkin accumulation in aggresomes due to proteasome impairment. J Biol Chem (2002) 1.30

Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci Lett (2002) 1.23

DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway. Hum Mol Genet (2012) 1.22

Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model. J Neurosci (2011) 1.20

DJ-1 protects against oxidative damage by regulating the thioredoxin/ASK1 complex. Neurosci Res (2010) 1.10

Casein kinase II-mediated phosphorylation regulates alpha-synuclein/synphilin-1 interaction and inclusion body formation. J Biol Chem (2003) 1.10

Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements. J Neurosci (2010) 0.97

Sustained activation of protein kinase C downregulates nuclear factor-kappaB signaling by dissociation of IKK-gamma and Hsp90 complex in human colonic epithelial cells. Carcinogenesis (2006) 0.96

Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J Neuroimmunol (2006) 0.96

Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications. Pharmacol Ther (2011) 0.91

Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson's disease. Neurotherapeutics (2013) 0.90

Apoptosis signal-regulating kinase 1 mediates MPTP toxicity and regulates glial activation. PLoS One (2012) 0.88

α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease. Rev Neurosci (2012) 0.88

Localization of CKII beta subunits in Lewy bodies of Parkinson's disease. J Neurol Sci (2007) 0.87

Proteasome inhibition induces α-synuclein SUMOylation and aggregate formation. J Neurol Sci (2011) 0.85

Human Polycomb protein 2 promotes α-synuclein aggregate formation through covalent SUMOylation. Brain Res (2011) 0.84

MicroRNAs in neurodegenerative disorders. Cell Cycle (2010) 0.84

Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov Disord (2011) 0.83

Synphilin-1 degradation by the ubiquitin-proteasome pathway and effects on cell survival. J Neurochem (2002) 0.83

IFN-beta gene transfer into the central nervous system using bone marrow cells as a delivery system. J Interferon Cytokine Res (2002) 0.82

Advances in gene therapy for movement disorders. Neurotherapeutics (2008) 0.79

Developmental expression of the zinc finger transcription factor DRRF (dopamine receptor regulating factor). Mech Dev (2002) 0.78

Alpha-synuclein in Parkinson's disease: light from two new angles. Ann Neurol (2004) 0.78

Targeting phosphatases as the next generation of disease modifying therapeutics for Parkinson's disease. Neurochem Int (2012) 0.78

Activation of the GDNF-inducible transcription factor (GIF) gene promoter by glucocorticoid and progesterone. J Steroid Biochem Mol Biol (2009) 0.78

Delivery of transgenically modified adult bone marrow cells to the rodent central nervous system. Expert Opin Biol Ther (2004) 0.76

Identification of bacteriophage K11 genomic promoters for K11 RNA polymerase. J Biochem Mol Biol (2002) 0.76

Transcriptional auto-regulation of the dopamine receptor regulating factor (DRRF) gene. Mol Cell Endocrinol (2008) 0.76

Should levodopa be infused into the duodenum? Neurology (2005) 0.75

Genomic organization and promoter characterization of the murine dopamine receptor regulating factor (DRRF) gene. Gene (2003) 0.75

Complications of a trophic xenotransplant approach in parkinsonian monkeys. Prog Neuropsychopharmacol Biol Psychiatry (2003) 0.75

Predicting the development of levodopa-induced dyskinesias: a presynaptic mechanism? Neurology (2014) 0.75